Issues in the use of adaptive clinical trial designs.

1. Summary: A discussion of a variety of issues that must be considered when using an adaptive clinical trial design.
   

2. Ref: Emerson SS, Statistics in Medicine 25: 3270-3296 (2006).
   

Adaptive Methods: Telling ‘The Rest of the Story’.

1. Summary:  A commentary on the draft FDA Guidance on adaptive designs.
   

2. Ref: Emerson SS, Fleming TR, Journal of Biopharmaceutical Statistics 20: 1150-1165 (2010).
   

Exploring the benefits of adaptive sequential designs in time-to-event endpoint settings.

1. Summary: When using a time to event as a primary endpoint there are some features that might suggest an advantage to a more adaptive approach.
   

2. Ref: Emerson SC, Rudser KD, Emerson SS, Statistics in Medicine 30:1199-1217 (2011).
   

Comments on “Adaptive increase in sample size when interim results are promising: A practical guide with examples”.

1. Summary: A commentary on a paper written by Mehta & Pocock (Statistics in Medicine)
   

2. Ref: Emerson SS, Levin GP, Emerson SC, Statistics in Medicine 30:3285-3301 (2011).
   

Adaptive clinical trial designs with pre-specified rules for modifying the sample size: Understanding efficient types of adaptation.

1. Summary: An exploration of efficient rules for adaptive modification of maximal sample size. 
   

2. Ref: Levin GP, Emerson SC, Emerson SS, (BEPress) (2011)
   

An Evaluation of Adaptive Clinical Trial Designs with Pre-specified Rules for Modifying the Sampling Plan

1. Summary: G. Levin’s Ph.D. Dissertation exploring adaptive designs that allow modification of the sampling plan, as well as exploring inferential procedures following termination of the clinical trial. 
   

2. Ref: Levin GP, University of Washington, Department of Biostatistics (2012)
   

Estimation Following Self-designing Clinical Trial

1. Summary: S Shi MS Thesis: A comparison of the MLE and self designing trial Z statistic for estimation following an adaptive RCT.
   

2. Ref: Shi S, University of Washington, Department of Biostatististics (2003)
   

3. 
   

Evaluation of Strategies for the Phase II to Phase III Progression in Treatment Discovery

1. Summary:  Brittany J. Sanchez Thesis: An investigation of the importance of well-planned progression from Phase II to Phase III RCT in order to ensure a sufficiently low false positive rate of adopting ineffective treatments (a low type 1 error), a sufficiently high probability of adopting truly effective treatments (a high statistical power), and a sufficiently high probability that adopted treatments will be truly effective (a high positive predictive value). Also investigated in the bias associated with early termination of group sequential RCT.
   

2. Ref: Sanchez BJ (2014)